Updated to include more background on variants and clinical trials in younger children, advice on offering boosters to 18 to 39 year olds, advice on boosters for severely immunosuppressed after a third dose, advice on second doses of vaccine for children aged 12 to 15 years and potential flexibility around schedules in under 18s in a changing epidemiological situation. Updates on 15 minute wait after mRNA vaccines and advice on heterologous primary courses. Updated risk for pregnancy and added reference to guidance on monitoring patients with a history of immune thrombocytopenia. Information on the paediatric product and advice about fractional doses. Updated to include JCVI advice on boosters for 16 and 17 and at risk 12 to 15 year olds, and primary immunisation for 5 to 11 year olds. Clarified clinical advice about vaccination of 5 to 11 year olds at high risk: interchangeability of adult, fractional and paediatric doses management of 5 to 11s who are about to become immunosuppressed advice on third primary doses for severe immunosuppression, including updated definitions for severe immunosuppression for younger children.

Updated background to include latest data on vaccine effectiveness and booster safety clarified and corrected chronology of booster advice. Updated to include: approval of Novavax, clarification around deferral after COVID-19 infection, one-off programme for 5 to 11 year olds who are not in clinical risk groups, advice on use of the paediatric formulation in those aged 12 years, spring booster recommendations (including flexibility around timing) and expectations for an autumn booster, clarification of the management of individuals with a history of allergic reactions, updated advice on management of people who have ITP following vaccination. Updated to include information on the autumn programme and variant vaccines, and further clarification of information on revaccination and capillary leak syndrome. Updated to include approval of Pfizer bivalent vaccine and further clarification around vaccination of under 12 year olds. Updated to include shortened background, separation between the historical pandemic response and the ongoing programme, spring booster campaign, explanation of the end of universal primary and booster offers, and describing the move to only offer vaccine during seasonal campaigns. Updated storage information for VidPrevtyn. Updated to include JCVI advice on vaccination for children aged 6 months to 4 years in a clinical risk group.

The last of us part 2 chapters